Pub Date : 2019-12-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.12.001
L. Bai, C. Jin, Shuangquan Wang
Objective To investigate the characterization of doxorubicin (DOX) coupling segmented copolymer nanomicelles with dual effects of passive and active targeting to liver cancer and its antineoplastic function in vitro. Methods DOX was covalently conjugated to a terminal hydroxyl group of poly lactic-co-glycolic acid-poly ethylene glycol (PLGA-PEG) diblock copolymer to form DOX-PLGA-PEG. The formation of amido bond was determined by using fourier transform infrared spectroscopy (FTIR) and magnetic resonance method. Amphiphatic diblock copolymer DOX-PLGA-PEG could self-assemble to form nanomicelles in an aqueous phase by dialysis method. The DOX-PLGA-PEG targeted micelles decorated with liver cancer HAb18 F (ab')2 specific antibody were prepared by using physical bonding method. The size and the scattering scope of nanomicelles was determined by using granulometer and dynamic light scattering (DLS). Micelle morphology was examined by using scanning electron microscopy (SEM). The drug loading rate and entrapment rate of DOX-PLGA-PEG micelles or targeted micelles were measured by using ultraviolet spectrophotometry method, and stimulated release in vitro experiment was done. After administration of 2 mg/ml DOX-PLGA-PEG or targeted micelles, cell morphology change of liver cancer HepG2 and Huh7 was observed by using the phase-contrast photomicrography. After administration of 1 mg/ml DOX-PLGA-PEG or targeted micelles, cell survival was analyzed by using plate clone formation assay. Results The spectrum peak was around 1 575 cm-1 under the observation of FTIR, which was accord with the location of the peak of amido bond. Activating with p-nitrophenyl chloroformate, DOX was covalently conjugated to PLGA-PEG to produce DOX-PLGA-PEG via a carbamate linkage between the primary amine group in DOX and the terminal hydroxyl group in PLGA-PEG. DLS measurements showed that the diameter of DOX-PLGA-PEG micelles and targeted micelles was (55.0±6.3) nm and (87.6±9.3) nm, respectively, and polydispersity index was 0.098 and 0.142, respectively. SEM micrographs revealed that these nanomicelles had a spherical morphology and relatively smooth surface. Drug loading rate of DOX-PLGA-PEG micelles and targeted micelles was (2.4±0.2)% and (2.2±1.9)%, and the entrapment rate was (91.7±5.3)% and (87.5±4.8)%, respectively. The drug release curve in vitro of DOX-PLGA-PEG micelles and targeted micelles exhibited a biphasic pattern characterized by a fast initial release, followed by a slower and continuous release. The amount of the drug release rate was about 30% within 5 d, and 25% within 6 h. After 2 mg/ml DOX-PLGA-PEG micelles and targeted micelles, the cell morphology of liver cancer HepG2 and Huh7 had the impaired change, and the part of the cells were dead, the clonality decreased. The effect of targeted micelles was more significant compared with DOX-PLGA-PEG micelles. After DOX-PLGA-PEG micelles and targeted micelles, the survival rates of HepG2 and Huh7 ce
{"title":"Characterization of liver cancer-targeted doxorubicin coupling segmented copolymer nanomicelles and its inhibitory effect on hepatocellular carcinoma HepG2 and Huh7 cells","authors":"L. Bai, C. Jin, Shuangquan Wang","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.001","url":null,"abstract":"Objective \u0000To investigate the characterization of doxorubicin (DOX) coupling segmented copolymer nanomicelles with dual effects of passive and active targeting to liver cancer and its antineoplastic function in vitro. \u0000 \u0000 \u0000Methods \u0000DOX was covalently conjugated to a terminal hydroxyl group of poly lactic-co-glycolic acid-poly ethylene glycol (PLGA-PEG) diblock copolymer to form DOX-PLGA-PEG. The formation of amido bond was determined by using fourier transform infrared spectroscopy (FTIR) and magnetic resonance method. Amphiphatic diblock copolymer DOX-PLGA-PEG could self-assemble to form nanomicelles in an aqueous phase by dialysis method. The DOX-PLGA-PEG targeted micelles decorated with liver cancer HAb18 F (ab')2 specific antibody were prepared by using physical bonding method. The size and the scattering scope of nanomicelles was determined by using granulometer and dynamic light scattering (DLS). Micelle morphology was examined by using scanning electron microscopy (SEM). The drug loading rate and entrapment rate of DOX-PLGA-PEG micelles or targeted micelles were measured by using ultraviolet spectrophotometry method, and stimulated release in vitro experiment was done. After administration of 2 mg/ml DOX-PLGA-PEG or targeted micelles, cell morphology change of liver cancer HepG2 and Huh7 was observed by using the phase-contrast photomicrography. After administration of 1 mg/ml DOX-PLGA-PEG or targeted micelles, cell survival was analyzed by using plate clone formation assay. \u0000 \u0000 \u0000Results \u0000The spectrum peak was around 1 575 cm-1 under the observation of FTIR, which was accord with the location of the peak of amido bond. Activating with p-nitrophenyl chloroformate, DOX was covalently conjugated to PLGA-PEG to produce DOX-PLGA-PEG via a carbamate linkage between the primary amine group in DOX and the terminal hydroxyl group in PLGA-PEG. DLS measurements showed that the diameter of DOX-PLGA-PEG micelles and targeted micelles was (55.0±6.3) nm and (87.6±9.3) nm, respectively, and polydispersity index was 0.098 and 0.142, respectively. SEM micrographs revealed that these nanomicelles had a spherical morphology and relatively smooth surface. Drug loading rate of DOX-PLGA-PEG micelles and targeted micelles was (2.4±0.2)% and (2.2±1.9)%, and the entrapment rate was (91.7±5.3)% and (87.5±4.8)%, respectively. The drug release curve in vitro of DOX-PLGA-PEG micelles and targeted micelles exhibited a biphasic pattern characterized by a fast initial release, followed by a slower and continuous release. The amount of the drug release rate was about 30% within 5 d, and 25% within 6 h. After 2 mg/ml DOX-PLGA-PEG micelles and targeted micelles, the cell morphology of liver cancer HepG2 and Huh7 had the impaired change, and the part of the cells were dead, the clonality decreased. The effect of targeted micelles was more significant compared with DOX-PLGA-PEG micelles. After DOX-PLGA-PEG micelles and targeted micelles, the survival rates of HepG2 and Huh7 ce","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41315327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.12.004
Hongjian Dou, Junling Han, Y. Xing
Objective To investigate the expressions of serum miRNA-126 (miR-126) and miRNA-30c (miR-30c) in patients with pancreatic cancer, and to analyze the relationship with the occurrence of pancreatic cancer as well as the diagnostic value. Methods A total of 110 patients with pancreatic cancer diagnosed at the 928th Hospital of the Joint Service Support Force of PLA from January 2014 to December 2018 were selected, and 110 healthy people were also selected as the control group. The expression levels of serum miR-126 and miR-30c of 110 patients and the healthy controls were detected by using real-time quantitative polymerase chain reaction (qRT-PCR), and their relationship with clinicopathological features of pancreatic cancer was analyzed. Results The levels of serum miR-126 and miR-30c in pancreatic cancer group were lower than those in the healthy control group (0.43±0.12 vs. 1.02±0.27, t = 19.394, P 0.05), but related with tumor size, differentiation degree, TNM stage and lymph node metastasis (all P < 0.05). High expression levels of serum miR-126 and miR-30c were protective factors for pancreatic cancer (all P < 0.05), while smoking, drinking and gallstones were risk factors for pancreatic cancer (all P < 0.05). The area under the curve of combined detection of serum miR-126 and miR-30c for diagnosis of pancreatic cancer was 0.906, the sensitivity was 90.80%, and the specificity was 82.20%. Conclusions The expression levels of serum miR-126 and miR-30c in patients with pancreatic cancer are low. Both of them may be involved in the occurrence and development of pancreatic cancer, and may be used as early diagnostic markers of pancreatic cancer. Key words: Pancreatic neoplasms; miRNA-126; miRNA-30c; Diagnosis
{"title":"Expressions of serum miRNA-126 and miRNA-30c in patients with pancreatic cancer and their clinical significances","authors":"Hongjian Dou, Junling Han, Y. Xing","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.004","url":null,"abstract":"Objective \u0000To investigate the expressions of serum miRNA-126 (miR-126) and miRNA-30c (miR-30c) in patients with pancreatic cancer, and to analyze the relationship with the occurrence of pancreatic cancer as well as the diagnostic value. \u0000 \u0000 \u0000Methods \u0000A total of 110 patients with pancreatic cancer diagnosed at the 928th Hospital of the Joint Service Support Force of PLA from January 2014 to December 2018 were selected, and 110 healthy people were also selected as the control group. The expression levels of serum miR-126 and miR-30c of 110 patients and the healthy controls were detected by using real-time quantitative polymerase chain reaction (qRT-PCR), and their relationship with clinicopathological features of pancreatic cancer was analyzed. \u0000 \u0000 \u0000Results \u0000The levels of serum miR-126 and miR-30c in pancreatic cancer group were lower than those in the healthy control group (0.43±0.12 vs. 1.02±0.27, t = 19.394, P 0.05), but related with tumor size, differentiation degree, TNM stage and lymph node metastasis (all P < 0.05). High expression levels of serum miR-126 and miR-30c were protective factors for pancreatic cancer (all P < 0.05), while smoking, drinking and gallstones were risk factors for pancreatic cancer (all P < 0.05). The area under the curve of combined detection of serum miR-126 and miR-30c for diagnosis of pancreatic cancer was 0.906, the sensitivity was 90.80%, and the specificity was 82.20%. \u0000 \u0000 \u0000Conclusions \u0000The expression levels of serum miR-126 and miR-30c in patients with pancreatic cancer are low. Both of them may be involved in the occurrence and development of pancreatic cancer, and may be used as early diagnostic markers of pancreatic cancer. \u0000 \u0000 \u0000Key words: \u0000Pancreatic neoplasms; miRNA-126; miRNA-30c; Diagnosis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45384610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Oncocytic schneiderian papilloma in maxillary sinus: report of one case and review of literature","authors":"He Qin","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.012","url":null,"abstract":"目的 \u0000探讨鼻窦嗜酸细胞乳头状瘤的临床特点、影像学特征、病理学特点和治疗策略。 \u0000 \u0000 \u0000方法 \u0000回顾性分析北京清华长庚医院收治的1例右侧上颌窦嗜酸细胞乳头状瘤患者的临床资料，结合相关文献进行分析，讨论该疾病的临床特点、诊断和治疗。 \u0000 \u0000 \u0000结果 \u0000该患者无临床症状，CT检查为细条状高密度影，磁共振成像（MRI）检查提示T1WI高信号、T2WI低信号影。术前误诊为真菌性鼻窦炎，术中见上颌窦壁附着有暗红色乳头状新生物，完整切除肿瘤，术后病理示嗜酸细胞乳头状瘤。术后随访2年未见复发和癌变。 \u0000 \u0000 \u0000结论 \u0000鼻窦嗜酸细胞乳头状瘤临床症状和影像学检查常不典型，术前要综合分析避免误诊，术中要完整切除肿瘤。术后肿瘤容易复发和恶变，需定期随访。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44550254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.12.008
Lin Quan, Ling-Tong Xu, Wenping Chen
Objective To investigate the clinical prognostic value of peripheral blood albumin and fibrinogen levels in advanced non-small cell lung cancer (NSCLC). Methods A total of 158 patients with advanced NSCLC who were admitted to Chest Hospital District of the Affiliated Brain Hospital of Nanjing Medical University from May 2010 to September 2015 were retrospectively analyzed. All patients received systemic chemotherapy plus or not local radiotherapy. The clinicopathological characteristics of patients and the results of peripheral serum protein and fibrinogen were collected, and the correlation between peripheral serum protein and fibrinogen levels and prognosis was analyzed. Results The median level of serum albumin and plasma fibrinogen was 40.8 g/L (27.6-46.9 g/L) and 3.4 g (2.4-5.2 g/L), respectively, and the median serum albumin and fibrinogen ratio (AFR) was 12.1 (6.2-17.0). The median overall survival (OS) time in the increased serum albumin group (≥40 g/L) and the decreased serum albumin group (<40 g/L) was 17.0 and 9.0 months, respectively, and the median OS time in the increased plasma fibrinogen group (≥40 g/L) and the decreased plasma fibrinogen group (<40 g/L) was 9.0 and 17.0 months, respectively. The median OS time in the increased AFR group (≥10) and decreased AFR group (<10) was 17.0 and 8.0 months, respectively, and there were significant differences between two groups (all P < 0.01). Multivariate analysis showed that serum albumin level (HR = 1.58, 95% CI 1.20-2.06, P = 0.003), plasma fibrinogen level (HR = 1.43, 95% CI 1.01-2.03, P = 0.046) and AFR (HR = 1.81, 95% CI 1.22-2.62, P = 0.001) were independent prognostic factors of OS. Conclusions In patients with advanced NSCLC, higher albumin level and/or lower fibrinogen level are associated with better clinical prognosis. Peripheral serum albumin, fibrinogen level and AFR are independent prognostic factors for advanced NSCLC. Key words: Cacinoma, non-small cell lung; Albumin; Fibrinogen; Prognosis
目的探讨外周血白蛋白和纤维蛋白原水平对晚期非小细胞肺癌(NSCLC)的临床预后价值。方法对2010年5月至2015年9月南京医科大学附属脑科医院胸科区收治的158例晚期非小细胞肺癌患者进行回顾性分析。所有患者均接受全身化疗加或不加局部放疗。收集患者临床病理特征及外周血蛋白、纤维蛋白原检测结果，分析外周血蛋白、纤维蛋白原水平与预后的相关性。结果血清白蛋白和血浆纤维蛋白原中位值分别为40.8 g/L (27.6 ~ 46.9 g/L)和3.4 g (2.4 ~ 5.2 g/L)，血清白蛋白与纤维蛋白原比值(AFR)中位值为12.1(6.2 ~ 17.0)。血清白蛋白升高组(≥40 g/L)和血清白蛋白降低组(<40 g/L)的中位总生存期(OS)分别为17.0和9.0个月，血浆纤维蛋白原升高组(≥40 g/L)和血浆纤维蛋白原降低组(<40 g/L)的中位总生存期(OS)分别为9.0和17.0个月。AFR升高组(≥10)和AFR降低组(<10)的中位OS时间分别为17.0和8.0个月，两组间差异有统计学意义(均P < 0.01)。多因素分析显示，血清白蛋白水平(HR = 1.58, 95% CI 1.20 ~ 2.06, P = 0.003)、血浆纤维蛋白原水平(HR = 1.43, 95% CI 1.01 ~ 2.03, P = 0.046)和AFR (HR = 1.81, 95% CI 1.22 ~ 2.62, P = 0.001)是OS的独立预后因素。结论在晚期NSCLC患者中，较高的白蛋白水平和/或较低的纤维蛋白原水平与较好的临床预后相关。外周血白蛋白、纤维蛋白原水平和AFR是晚期非小细胞肺癌的独立预后因素。关键词:肺癌;非小细胞肺;白蛋白;纤维蛋白原;预后
{"title":"Value of peripheral blood albumin and fibrinogen levels in the prognostic evaluation of advanced non-small cell lung cancer","authors":"Lin Quan, Ling-Tong Xu, Wenping Chen","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.008","url":null,"abstract":"Objective \u0000To investigate the clinical prognostic value of peripheral blood albumin and fibrinogen levels in advanced non-small cell lung cancer (NSCLC). \u0000 \u0000 \u0000Methods \u0000A total of 158 patients with advanced NSCLC who were admitted to Chest Hospital District of the Affiliated Brain Hospital of Nanjing Medical University from May 2010 to September 2015 were retrospectively analyzed. All patients received systemic chemotherapy plus or not local radiotherapy. The clinicopathological characteristics of patients and the results of peripheral serum protein and fibrinogen were collected, and the correlation between peripheral serum protein and fibrinogen levels and prognosis was analyzed. \u0000 \u0000 \u0000Results \u0000The median level of serum albumin and plasma fibrinogen was 40.8 g/L (27.6-46.9 g/L) and 3.4 g (2.4-5.2 g/L), respectively, and the median serum albumin and fibrinogen ratio (AFR) was 12.1 (6.2-17.0). The median overall survival (OS) time in the increased serum albumin group (≥40 g/L) and the decreased serum albumin group (<40 g/L) was 17.0 and 9.0 months, respectively, and the median OS time in the increased plasma fibrinogen group (≥40 g/L) and the decreased plasma fibrinogen group (<40 g/L) was 9.0 and 17.0 months, respectively. The median OS time in the increased AFR group (≥10) and decreased AFR group (<10) was 17.0 and 8.0 months, respectively, and there were significant differences between two groups (all P < 0.01). Multivariate analysis showed that serum albumin level (HR = 1.58, 95% CI 1.20-2.06, P = 0.003), plasma fibrinogen level (HR = 1.43, 95% CI 1.01-2.03, P = 0.046) and AFR (HR = 1.81, 95% CI 1.22-2.62, P = 0.001) were independent prognostic factors of OS. \u0000 \u0000 \u0000Conclusions \u0000In patients with advanced NSCLC, higher albumin level and/or lower fibrinogen level are associated with better clinical prognosis. Peripheral serum albumin, fibrinogen level and AFR are independent prognostic factors for advanced NSCLC. \u0000 \u0000 \u0000Key words: \u0000Cacinoma, non-small cell lung; Albumin; Fibrinogen; Prognosis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46251415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To improve understanding of the accelerated phase of chronic myeloid leukemia (CML-AP) in children with EVI1 gene positivity. Method: A retrospective analysis was conducted on the clinical data of one EVI1 gene positive child CML-AP patient admitted to Qingdao Women and Children's Hospital in January 2019, and relevant literature was reviewed. The patient, male, 14 years old, was diagnosed and received a combination of domestic imatinib and low-dose chemotherapy, achieving complete hematological remission. The quantification of BCR-ABL p210 decreased to 4.66%, and the quantification of EVI1 decreased to normal (0.01%). Conclusion: CML-AP in children is rare, and its clinical features mainly include a significant increase in white blood cell count and splenomegaly. The combination of domestic imatinib and low-dose chemotherapy is effective in the treatment of CML-AP in children with EVI1 gene positivity, but the long-term efficacy still needs close follow-up.
{"title":"Childhood chronic myeloid leukemia in accelerated phase with EVI1 positive: report of one case and review of literature","authors":"C. Zhuang, Xiuxia Chen, Pingping Wei, Liang Hui","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.013","url":null,"abstract":"目的 \u0000提高对EVI1基因阳性的儿童慢性粒细胞白血病加速期（CML-AP）的认识。 \u0000 \u0000 \u0000方法 \u0000回顾性分析青岛市妇女儿童医院2019年1月收治的1例EVI1基因阳性的儿童CML-AP患者的临床资料，并复习相关文献。 \u0000 \u0000 \u0000结果 \u0000患儿，男性，14岁，确诊后，加用国产伊马替尼联合小剂量化疗方案，达血液学完全缓解。BCR-ABL p210定量降至4.66%，EVI1定量降至正常（0.01%）。 \u0000 \u0000 \u0000结论 \u0000儿童CML-AP罕见，临床特征主要为白细胞计数明显升高和巨脾。国产伊马替尼联合小剂量化疗方案对EVI1基因阳性的儿童CML-AP治疗有效，远期疗效尚需密切随访。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49304669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Acute pancreatitis-onset of chronic myelogenous leukemia with transformation into extramedullary acute lymphoblastic leukemia: report of one case and review of literature","authors":"Xin Su, Chengshun Chen","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.011","url":null,"abstract":"目的 \u0000探讨以不典型症状起病的慢性粒细胞白血病（CML）发生髓外急性淋巴细胞白血病（ALL）转变的临床影像学特征及诊疗方法。 \u0000 \u0000 \u0000方法 \u0000回顾性分析北京中医药大学东直门医院收治的1例以急性胰腺炎起病的CML髓外ALL转变患者临床资料，并复习相关文献。 \u0000 \u0000 \u0000结果 \u0000该患者确诊为CML慢性期，伊马替尼治疗10个月后，突发左侧中上腹疼痛，进食后加重，血清脂肪酶水平升高，多发皮下结节，影像学改变符合急性胰腺炎，予抗感染、对症治疗无效。3 d后经骨髓穿刺明确诊断为CML急性期，ALL转变，高度怀疑白血病细胞浸润胰腺，立即开始达沙替尼联合VDCD方案治疗，48 h后血清脂肪酶降至正常，腹痛、腹胀症状消失，皮下结节迅速缩小、消退，临床符合ALL胰腺、皮肤浸润。 \u0000 \u0000 \u0000结论 \u0000CML髓外ALL转变发生于胰腺较为少见，及时评价药物疗效，加强BCR-ABL融合基因及ABL激酶突变检测，对发现疾病进展有积极意义。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective To investigate the value of enhanced recovery after surgery (ERAS) in D2 radical resection of distal gastric cancer under total laparoscopy and its effect on inflammatory factors. Methods The clinical data of 50 patients with distal gastric cancer at Hanzhong Central Hospital from March 2016 to October 2017 were retrospectively analyzed. The patients were divided into the observation group (25 cases) and the control group (25 cases). The observation group received totally laparoscopic radical D2 gastrectomy for distal gastric cancer under the guideline of ERAS; the control group received totally laparoscopic radical D2 gastrectomy for distal gastric cancer under the guideline of the traditional method. The changes of perioperative related indexes, postoperative recovery and postoperative inflammatory indexes were compared between the two groups. Results All 50 patients successfully completed the operation. The operation time was (287.2±52.3) min and (296.8±57.9) min, respectively of the observation group and the control group; the number of lymph node dissection was (34.0±11.0) and (34.6±14.3), respectively of the observation group and the control group. There were no significant differences in the above indexes between the two groups (all P > 0.05). The hospitalization time, the hospitalization cost, the postoperative time of getting out of bed of the observation group was (22.0±2.8) d, (61 044.4±4 692.7) yuan, (12.8±1.8) h. The hospitalization time, the hospitalization cost, the postoperative time of getting out of bed of the control group was (23.9±1.9) d, (63 875.81±4 392.6) yuan, (23.7±8.2) h. And there were statistically significant differences between the two groups (all P 0.05). There were no statistically significant differences in the tumor necrosis factor α, interleukin-6 (IL-6), C-reactive protein and procalcitonin on the day before the operation of both groups (all P > 0.05); the levels of above four factors in the observation group were lower than those in the control group on the 1st, 4th and 7th day after the operation, and the differences were statistically significant (all P < 0.05). Conclusion The application of ERAS in totally laparoscopic radical resection of gastric cancer can improve the postoperative condition, significantly reduce the inflammatory reaction of patients, which has a certain value of improving the quality of life of patients. Key words: Gastric neoplasms; Laparoscopy, D2 radical resection; Inflammation; Cytokines; Enhanced recovery after surgery
{"title":"Value of enhanced recovery after surgery in D2 radical resection of distal gastric cancer under total laparoscopy and its effect on inflammatory factors","authors":"Weisong Bai, Lizhi Zhao, Jiquan Tang, Li Shen, Zhicheng Shen, Shouli Wang, Zhiwei Wang, Jia Xu","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.006","url":null,"abstract":"Objective \u0000To investigate the value of enhanced recovery after surgery (ERAS) in D2 radical resection of distal gastric cancer under total laparoscopy and its effect on inflammatory factors. \u0000 \u0000 \u0000Methods \u0000The clinical data of 50 patients with distal gastric cancer at Hanzhong Central Hospital from March 2016 to October 2017 were retrospectively analyzed. The patients were divided into the observation group (25 cases) and the control group (25 cases). The observation group received totally laparoscopic radical D2 gastrectomy for distal gastric cancer under the guideline of ERAS; the control group received totally laparoscopic radical D2 gastrectomy for distal gastric cancer under the guideline of the traditional method. The changes of perioperative related indexes, postoperative recovery and postoperative inflammatory indexes were compared between the two groups. \u0000 \u0000 \u0000Results \u0000All 50 patients successfully completed the operation. The operation time was (287.2±52.3) min and (296.8±57.9) min, respectively of the observation group and the control group; the number of lymph node dissection was (34.0±11.0) and (34.6±14.3), respectively of the observation group and the control group. There were no significant differences in the above indexes between the two groups (all P > 0.05). The hospitalization time, the hospitalization cost, the postoperative time of getting out of bed of the observation group was (22.0±2.8) d, (61 044.4±4 692.7) yuan, (12.8±1.8) h. The hospitalization time, the hospitalization cost, the postoperative time of getting out of bed of the control group was (23.9±1.9) d, (63 875.81±4 392.6) yuan, (23.7±8.2) h. And there were statistically significant differences between the two groups (all P 0.05). There were no statistically significant differences in the tumor necrosis factor α, interleukin-6 (IL-6), C-reactive protein and procalcitonin on the day before the operation of both groups (all P > 0.05); the levels of above four factors in the observation group were lower than those in the control group on the 1st, 4th and 7th day after the operation, and the differences were statistically significant (all P < 0.05). \u0000 \u0000 \u0000Conclusion \u0000The application of ERAS in totally laparoscopic radical resection of gastric cancer can improve the postoperative condition, significantly reduce the inflammatory reaction of patients, which has a certain value of improving the quality of life of patients. \u0000 \u0000 \u0000Key words: \u0000Gastric neoplasms; Laparoscopy, D2 radical resection; Inflammation; Cytokines; Enhanced recovery after surgery","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48546642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.12.007
Xin Ma, Yuanyi Wen, Yong Wang, M. Zhang, Fujun Liu
Objective To investigate the correlation between CXC chemokine receptor 6 (CXCR6) and prognosis of renal clear cell carcinoma. Methods A total of 100 patients with renal clear cell carcinoma who underwent surgery in the First People's Hospital of Ziyang from January 2013 to October 2014 were selected. Immunohistochemistry was used to detect the expression of CXCR6 in 100 cases of renal clear cell carcinoma and adjacent normal tissues. The patients were followed up to observe the positive rate of CXCR6 expression and the factors affecting overall survival (OS) and progression-free survival (PFS) of renal clear cell carcinoma and adjacent normal tissues. Results The positive rate of CXCR6 expression in renal clear cell carcinoma tissues was higher than that in adjacent tissues, and the difference was statistically significant [46.0% (46/100) vs. 20.0% (20/100), χ2 = 15.287, P < 0.01]. The positive expression rate of CXCR6 in patients with clinical stage Ⅲ-Ⅳ, lymph node metastasis and pathological grade Ⅲ-Ⅳ was higher than that in patients with clinical stage Ⅰ- Ⅱ, pathological grade Ⅰ- Ⅱ and without lymph node metastasis, and the difference was statistically significant (all P < 0.05). A total of 92 patients were followed up and 40 died. The follow-up time reached to (35-60) months and the median follow-up time was 48.9 months. Kaplan-Meier and log-rank test showed that patients with positive CXCR6 expression had lower 3-year OS and PFS rate compared with patients with negative CXCR6 expression, and the difference was statistically significant (3-year OS rate: 52.1% vs. 78.6%, χ2 = 10.027, P = 0.001; 3-year PFS rate: 48.3% vs. 67.8%, χ2 = 4.344, P = 0.037). Cox regression multivariate analysis showed pathological grade (OS: OR = 2.154, 95% CI 1.547-9.517, P = 0.023; PFS: OR = 1.235, 95% CI 1.109-5.917, P = 0.042), lymph node metastasis (OS: OR = 1.412, 95% CI 1.109-5.917, P = 0.041; PFS: OR = 1.841, 95% CI 1.354-8.994, P = 0.010), CXCR6 expression (OS: OR = 1.864, 95% CI 1.358-6.813, P = 0.031; PFS: OR = 1.457, 95% CI 1.127-6.884,P = 0.025) were independent risk factors of OS and PFS for renal clear cell carcinoma patients treated by the surgery. Conclusions The positive expression of CXCR6 is an independent risk factor for OS and PFS of renal clear cell carcinoma. The prognosis of patients with positive CXCR6 expression is poor. Key words: Carcinoma, renal cell; Receptors, chemokine; Prognosis
目的探讨肾透明细胞癌CXC趋化因子受体6 (CXCR6)与预后的关系。应用免疫组化方法检测CXCR6在100例肾透明细胞癌及邻近正常组织中的表达。对患者进行随访，观察CXCR6表达阳性率及影响肾透明细胞癌及邻近正常组织总生存期(OS)和无进展生存期(PFS)的因素。结果肾透明细胞癌组织中CXCR6表达阳性率高于癌旁组织，差异有统计学意义[46.0%(46/100)比20.0% (20/100)，χ2 = 15.287, P < 0.01]。临床分期Ⅲ-Ⅳ、淋巴结转移及病理分级Ⅲ-Ⅳ患者中CXCR6阳性表达率高于临床分期Ⅰ-Ⅱ、病理分级Ⅰ-Ⅱ及无淋巴结转移患者，差异均有统计学意义(P < 0.05)。随访92例，死亡40例。随访时间35 ~ 60个月，中位随访时间48.9个月。Kaplan-Meier和log-rank检验显示，CXCR6表达阳性患者的3年OS和PFS率低于CXCR6表达阴性患者，差异有统计学意义(3年OS率:52.1%比78.6%，χ2 = 10.027, P = 0.001;3年PFS率:48.3%比67.8%，χ2 = 4.344, P = 0.037)。Cox回归多因素分析显示病理分级(OS: OR = 2.154, 95% CI 1.547 ~ 9.517, P = 0.023;PFS: OR = 1.235, 95% CI 1.109-5.917, P = 0.042)，淋巴结转移(OS: OR = 1.412, 95% CI 1.109-5.917, P = 0.041;PFS: OR = 1.841, 95% CI 1.354-8.994, P = 0.010)， CXCR6表达(OS: OR = 1.864, 95% CI 1.358-6.813, P = 0.031;PFS: OR = 1.457, 95% CI 1.127 ~ 6.884,P = 0.025)是手术治疗肾透明细胞癌患者OS和PFS的独立危险因素。结论CXCR6阳性表达是肾透明细胞癌OS和PFS的独立危险因素。CXCR6阳性表达的患者预后较差。关键词:癌;肾细胞;趋化因子受体;预后
{"title":"Correlation analysis between CXC chemokine receptor 6 and prognosis of renal clear cell carcinoma","authors":"Xin Ma, Yuanyi Wen, Yong Wang, M. Zhang, Fujun Liu","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.007","url":null,"abstract":"Objective \u0000To investigate the correlation between CXC chemokine receptor 6 (CXCR6) and prognosis of renal clear cell carcinoma. \u0000 \u0000 \u0000Methods \u0000A total of 100 patients with renal clear cell carcinoma who underwent surgery in the First People's Hospital of Ziyang from January 2013 to October 2014 were selected. Immunohistochemistry was used to detect the expression of CXCR6 in 100 cases of renal clear cell carcinoma and adjacent normal tissues. The patients were followed up to observe the positive rate of CXCR6 expression and the factors affecting overall survival (OS) and progression-free survival (PFS) of renal clear cell carcinoma and adjacent normal tissues. \u0000 \u0000 \u0000Results \u0000The positive rate of CXCR6 expression in renal clear cell carcinoma tissues was higher than that in adjacent tissues, and the difference was statistically significant [46.0% (46/100) vs. 20.0% (20/100), χ2 = 15.287, P < 0.01]. The positive expression rate of CXCR6 in patients with clinical stage Ⅲ-Ⅳ, lymph node metastasis and pathological grade Ⅲ-Ⅳ was higher than that in patients with clinical stage Ⅰ- Ⅱ, pathological grade Ⅰ- Ⅱ and without lymph node metastasis, and the difference was statistically significant (all P < 0.05). A total of 92 patients were followed up and 40 died. The follow-up time reached to (35-60) months and the median follow-up time was 48.9 months. Kaplan-Meier and log-rank test showed that patients with positive CXCR6 expression had lower 3-year OS and PFS rate compared with patients with negative CXCR6 expression, and the difference was statistically significant (3-year OS rate: 52.1% vs. 78.6%, χ2 = 10.027, P = 0.001; 3-year PFS rate: 48.3% vs. 67.8%, χ2 = 4.344, P = 0.037). Cox regression multivariate analysis showed pathological grade (OS: OR = 2.154, 95% CI 1.547-9.517, P = 0.023; PFS: OR = 1.235, 95% CI 1.109-5.917, P = 0.042), lymph node metastasis (OS: OR = 1.412, 95% CI 1.109-5.917, P = 0.041; PFS: OR = 1.841, 95% CI 1.354-8.994, P = 0.010), CXCR6 expression (OS: OR = 1.864, 95% CI 1.358-6.813, P = 0.031; PFS: OR = 1.457, 95% CI 1.127-6.884,P = 0.025) were independent risk factors of OS and PFS for renal clear cell carcinoma patients treated by the surgery. \u0000 \u0000 \u0000Conclusions \u0000The positive expression of CXCR6 is an independent risk factor for OS and PFS of renal clear cell carcinoma. The prognosis of patients with positive CXCR6 expression is poor. \u0000 \u0000 \u0000Key words: \u0000Carcinoma, renal cell; Receptors, chemokine; Prognosis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47940987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.12.010
Ruiyun Liu, W. Gao, Xiaokun Li, Qiaohong Niu
Objective To develop a scientific oncology missed nursing care self-rating scale suitable for hospital culture background in China, and to test its validity and reliability. Methods The initial scale was formulated by literature review, qualitative interview and delphi expert consultation. A total of 388 clinical nurses from Shanxi Province were selected by convenience sampling. Item analysis was used to filtrate items. The validity was evaluated by using evaluation scale of construction and content validity, and the reliability was tested by using internal consistency, split-half reliability and retest reliability. Results Oncology missed nursing care self-rating scale consisted of 33 items and 4 dimensions including nursing assessment, nursing plan, basic nursing and nursing intervention. Exploratory factor analysis (EFA) revealed that 4 factors accounted for 63.664% of the accumulated variances. The scale-level content validity index (S-CVI) was 0.904. The Cronbach α coefficient was 0.948, the spilt-half reliability coefficient was 0.786, and the retest reliability coefficient was 0.833. Conclusion Oncology missed nursing care self-rating scale has good validity and reliability, which can be used as a measuring tool for oncology missed nursing care. Key words: Neoplasms; Oncologic nursing; Scale; Reliability; Validity
{"title":"Development and psychometric test of oncology missed nursing care self-rating scale","authors":"Ruiyun Liu, W. Gao, Xiaokun Li, Qiaohong Niu","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.010","url":null,"abstract":"Objective \u0000To develop a scientific oncology missed nursing care self-rating scale suitable for hospital culture background in China, and to test its validity and reliability. \u0000 \u0000 \u0000Methods \u0000The initial scale was formulated by literature review, qualitative interview and delphi expert consultation. A total of 388 clinical nurses from Shanxi Province were selected by convenience sampling. Item analysis was used to filtrate items. The validity was evaluated by using evaluation scale of construction and content validity, and the reliability was tested by using internal consistency, split-half reliability and retest reliability. \u0000 \u0000 \u0000Results \u0000Oncology missed nursing care self-rating scale consisted of 33 items and 4 dimensions including nursing assessment, nursing plan, basic nursing and nursing intervention. Exploratory factor analysis (EFA) revealed that 4 factors accounted for 63.664% of the accumulated variances. The scale-level content validity index (S-CVI) was 0.904. The Cronbach α coefficient was 0.948, the spilt-half reliability coefficient was 0.786, and the retest reliability coefficient was 0.833. \u0000 \u0000 \u0000Conclusion \u0000Oncology missed nursing care self-rating scale has good validity and reliability, which can be used as a measuring tool for oncology missed nursing care. \u0000 \u0000 \u0000Key words: \u0000Neoplasms; Oncologic nursing; Scale; Reliability; Validity","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49192367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.12.018
Xu Lu
Multiple myeloma (MM) is a common disease in the blood system, which mostly occurs in the middle-aged and the senior people. The pathogenesis of MM is not clear and MM can not be completely cured at present. Recent studies have found that microRNA (miRNA) plays a key role in the occurrence and development of MM. In addition, MM cells can release extracellular vesicle (EV), and involve in the intercellular information transmission and regulation. This paper reviews the role of EV in the development of MM. Key words: Multiple myeloma; Extracellular vesicle; Exosomes; MicroRNAs
{"title":"Progress of extracellular vesicle and its microRNA in multiple myeloma","authors":"Xu Lu","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.018","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.018","url":null,"abstract":"Multiple myeloma (MM) is a common disease in the blood system, which mostly occurs in the middle-aged and the senior people. The pathogenesis of MM is not clear and MM can not be completely cured at present. Recent studies have found that microRNA (miRNA) plays a key role in the occurrence and development of MM. In addition, MM cells can release extracellular vesicle (EV), and involve in the intercellular information transmission and regulation. This paper reviews the role of EV in the development of MM. Key words: Multiple myeloma; Extracellular vesicle; Exosomes; MicroRNAs","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47794292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：